AE230175

PPL Standard Condition 18 Notification Form

Please use this form to notify the Animals in Science Regulation Unit (ASRU) of procedural-related adverse effects that have exceeded or are likely to exceed the severity limitations or controls described in the project licence. ASRU will use this information to determine whether any further action is required.

Do not use to report:

- adverse effects that are due to non-procedural issues;
- potential non-compliance (report by other means);
- issues without adverse welfare consequences.

If you are in doubt whether or not you need to fill in this form, please contact your assigned Inspector.

Please clearly title your document: **'ASRU_establishment name_PPL number_PPLh surname_date_sc18'** and send to your Inspector (e.g. using cjsm) with the subject heading 'PPL SC 18 Notification PPL [Number] – **Check Home Office's Updated Bridging Ways of Working for updated advice on email addresses and subject headings. Cjsm no longer necessary.**

Establishment Licence name	Designated area within the University of Cambridge, Anne Maclaren Building
Establishment Licence number	X81BD37B1
Name of PPL holder	Brian Huntly
PPL number	PP3042348 (Huntly) Investigation of normal haematopietic stem cell subversion and the evolution, maintenance and targeting of haematological malignancies
Protocol no	9
Protocol title	[Moderate] 09 Study of the genetic and therapeutic vulnerabilities of pre-leukaemia and leukaemia (Mice)
Severity classification	Moderate
1. Date of incident	16/06/2023
2. Species	Mouse

3. Brief details of study and how the limits or constraints have been breached	The specific study uses a murine leukemic cell line in order to assess the therapeutic efficacy of HAT and/or Brd4 inhibition in this context. As such, mice under this study plan had received a sub-lethal dose of irradiation (on the 2nd of June 2023) followed by intravenous injection of murine cells. Follow up analyses confirmed engraftment and treatment commenced on 13th of June 2023. The study is comprised of 28 mice. One mouse on study plan SP132156 was found moribund on Friday 16th of June 2023.
4. Have you taken advice from the Named Animal Care and Welfare Officer/Named Veterinary Surgeon/others?	The animal was found moribund by AMB staff and was sacrificed following advice from the NACWO. The NAWCO was able to advise on the remainder of the cohort (please see section 6) as well as on one additional animal from this cohort that was found dead (a separate SC18 will be submitted).
5. Cause of Problem, if known	Leukaemic disease progression. Macroscopic examination of the animal demonstrated splenomegaly, (an obligate phenotype for this model system). This animal had been visually inspected on the previous day by both the AMB staff and two members of the lab, and displayed no clinical symptoms. The animal had been weighted on the previous day with a 5% weight loss recorded.
6. Action that has been or will be taken *(For example, formulation of drug changed, supportive treatment given, study design modified). If no action needed, indicate why (for example, none required as study has been terminated and will not be repeated)*	The remaining animals in this cohort (n=26) were weighted again today (16th of June2023) and visually inspected for any signs of distress or ill health. Two more animals (in agreement with the NACWOs assessment) were sacrificed as they displayed symptoms in line with moderate severity. Their blood parameters are in agreement with disease progression (elevated white blood counts) and we have observed splenomegaly too. The remainder of the mice will continue to be monitored twice daily, and weighted daily.
7. Reported by (name)	George Giotopoulos
8. Date	16/06/2023

**********For official use**********

Inspector's comments and recommendations:

Comments and recommendations	
Inspector name	
Date	